Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 9, 2010, Pages 697-712

  Cox, Christopher D ^a   Garbaccio, Robert M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anti mitotic; Eg5; hERG; Mitotic arrest; P glycoprotein (Pgp); QTc prolongation

Indexed keywords

3 FLUORO 4 (N METHYL) PIPERIDINE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; ISPINESIB; KINESIN SPINDLE PROTEIN; MK 0731; MOLECULAR MOTOR; PACLITAXEL; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER PATIENT; CARCINOID; CHILL; COLON CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG DESIGN; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; FEVER; FLUORINATION; HEADACHE; HUMAN; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; OPEN STUDY; OVARY CANCER; PATIENT SELECTION; PROSTATE CANCER; RECURRENT CANCER; SIDE EFFECT; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TAXANE REFRACTORY CANCER; TREATMENT RESPONSE; VOMITING;

EID: 79551635896     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010794479807     Document Type: Article

References (45)

1. Nadal, E.; Olavarria, E. Imatinib mesylate (Gleevec/Glivec) a molecular- targeted therapy for chronic myeloid leukaemia and other malignancies. J. Clin. Pract. 2004, 58, 511-516.
2. Sun, S.; Schiller, J. H.; Spinola, M.; Minna, J. D. New molecularly targeted therapies for lung cancer. J. Clin. Investig. 2007, 117, 2740-2750.
3. Conlin, A. K.; Seidman, A. D. Taxanes in breast cancer: An update. Curr. Oncol. Rep., 2007, 9, 22-30.
4. Miglarese, M. R.; Carlson, R. O. Development of new cancer therapeutic agents targeting mitosis. Expert Opin. Investig. Drugs 2006, 15, 1411-1425.
5. Schmidt, M.; Bastians, H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist. Updates 2007, 10, 162-181.
6. Wood, K. W.; Cornwell, W. D.; Jackson, J. R. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol. 2001, 1, 370-377.
7. Jackson, J. R.; Patrick, D. R.; Dar, M. M.; Huang, P. S. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat. Rev. Cancer 2007, 7, 107-117.
8. Goldstein, L. S. B.; Philp, A. V. The road less traveled: Emerging principles of kinesin motor utilization. Annu. Rev. Cell Div. Biol. 1999, 15, 141-183.
9. Sharp, D. J.; Rogers, G. C.; Scholey, J. M. Microtubule motors in mitosis. Nature 2000, 407, 41-47.
10. Bergnes, G.; Brejc, K.; Belmont, L. Mitotic kinesins: Prospects for antimitotic drug discovery. Curr. Top. Med. Chem. 2005, 5, 127-145.
11. Mayer, T. U.; Kapoor, T. M.; Haggarty, S. J.; King, R. W.; Schreiber, S. L.; Mitchison, T. J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999, 286, 971-974.
12. Sakowicz, R.; Finer, J. T.; Beraud, C.; Crompton, A.; Lewis, E.; Fritsch, A.; Lee, Y.; Mak, J.; Moody, R.; Turincio, R.; Chabala, J. C.; Gonzales, P.; Roth, S.; Weitman, S.; Wood, K. W. Antitumor activity of a kinesin inhibitor. Cancer Res. 2004, 64, 3276-3280.
13. Dutcher, J. P.; Novik, Y.; O'Boyle, K.; Marcoullis, G.; Secco, C.; Wiernik, P. H. 20th-Century advances in drug therapy in oncology- Part II. J. Clin. Pharmacol. 2000, 40, 1079-1092.
14. For a review of Pgp's relevance to drug discovery, see: Lin, J. H.; Yamazaki, M. Clinical Relevance of P-Glycoprotein in Drug Therapy. Drug Metab. Rev. 2003, 35, 417-454.
15. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Disc., 2006, 5, 219-234.
16. Roden, D. M. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 2004, 350, 1013-1022.
17. Cox, C. D.; Breslin, M. J.; Mariano, B. J.; Coleman, P. J.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Huber, H. E.; Kohl, N. E.; Torrent, M.; Yan, Y.; Kuo, L. C.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem. Lett. 2005, 15, 2041-2045.
18. Yan, Y.; Sardana, V.; Xu, B.; Homnick, C.; Halczenko, W.; Buser, C. A.; Schaber, M.; Hartman, G. D.; Huber, H. E.; Kuo, L. C. Inhibition of a mitotic motor protein: Where, how, and conformational consequences. J. Mol. Biol. 2004, 335, 547-554.
19. Cox, C. D.; Torrent, M.; Breslin, M. J.; Mariano, B. J.; Whitman, D. B.; Coleman, P. J.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Schaber, M. D.; Lobell, R. B.; Tao, W.; South, V. J.; Kohl, N. E.; Yan, Y.; Kuo, L. C.; Prueksaritanont, T.; Slaughter, D. E.; Li, C.; Mahan, E.; Lu, B.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part 4: Structure-based design of 5-alkylamino-3,5- diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the miotic kinesin KSP. Bioorg. Med. Chem. Lett. 2006, 16, 3175-3179.
20. Cox, C. D.; Breslin, M. J.; Mariano, B. J. Two step synthesis of TT- alkyl chalcones and their use in the synthesis of 3,5-diaryl-5-alkyl- 4,5-dihydropyrazoles. Tetrahedron Lett. 2004, 45, 1489-1492.
21. Fraley M. E.; Garbaccio, R. M.; Arrington, K. L.; Hoffman, W. F.; Tasber, E. S.; Coleman, P. J.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Fernandez, C.; Schaber, M. D.; Lobell, R. B.; Tao, W.; South, V. J.; Yan, Y.; Kuo, L. C.; Prueksaritanont, T.; Shu, C.; Torrent, M.; Heimbrook, D. C.; Kohl, N. E.; Huber, H. E.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem. Lett. 2006, 16, 1775-1779.
22. Carpes, M. J. S.; Correia, C. R. D. Heck arylation of N-Boc-3- pyrrolines and N-Boc-2-pyrrolines with diazonium salts; efficient syntheses of five-membered 4-aryl endocyclic enecarbamates and N-Boc-2,4-diaryl 3-pyrrolines. Synlett., 2000, 1037-1039.
23. Garbaccio, R. M.; Fraley, M. E.; Tasber, E. S.; Olson, C. M.; Hoffman, W. F.; Arrington, K. L.; Torrent, M.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Schaber, M. D.; Fernandez, C.; Lobell, R. B.; Tao, W.; South, V. J.; Yan, Y.; Kuo, L. C.; Prueksaritanont, T.; Slaughter, D. E.; Shu, C.; Heimbrook, D. C.; Kohl, N E.; Huber, H. E.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part 3: Synthesis and evaluation of phenolic 2,4-diaryl-2,5- dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility. Bioorg. Med. Chem. Lett. 2006, 16, 1780-1783.
24. Tao, W.; South, V. J.; Zhang, Y.; Davide, J P.; Farrell, L.; Kohl, N. E.; Sepp-Lorenzino, L.; Lobell, R. B. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005, 8, 49-59.
25. Crosio, C.; Fimia, G. M.; Loury, R.; Kimura, M.; Okano, Y.; Zhou, H.; Sen, S.; Allis, C. D.; Sassone-Corsi, P. Mitotic phosphorylation of histone H3: Spatio-temporal regulation by mammalian aurora kinases. Mol. Cell Biol. 2002, 22, 874-885.
26. Vide infra for an explanation of what in vitro properties we believe are most predictive of in vivo efficacy.
27. Zhou, S.; Chan, E.; Duan, W.; Huang, M.; Chen, Y.-Z. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 2005, 37, 41-213.
28. Cox, C. D.; Breslin, M. J.; Whitman, D. B.; Coleman, P. J.; Garbaccio, R. M.; Fraley, M. E.; Zrada, M. M.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Lobell, R. B.; Tao, W.; Abrams, M. T.; South, V. J.; Huber, H. E.; Kohl, N. E.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part 5: Discovery of 2-propylamino-2,4- diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by aa-fluorination to overcome cellular efflux by P-glycoprotein. Bioorg. Med. Chem. Lett. 2007, 17, 2697-2702.
29. Salerno, M.; Przewloka, T.; Fokt, I.; Priebe, W.; Garnier-Suillerot, A. Preferential efflux by P-glycoprotein, but not MRP1, of compounds containing a free electron donor amine. Biochem. Pharmacol. 2002, 63, 1471-1479.
30. Kaiser, D.; Smiesko, M.; Kopp, S.; Chiba, P.; Ecker, G. F. Interaction field based and hologram based QSAR analysis of propafenone-type modulators of multidrug resistance. Med. Chem. 2005, 1, 431-444 and references therein.
31. Cox, C.D.; Coleman, P. J.; Breslin, M. J.; Whitman, D. B.; Garbaccio, R. M.; Fraley, M. E.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Schaber, M. D.; Lobell, R. B.; Tao, W.; Davide, J. P.; Diehl, R. E.; Abrams, M. T.; South, V. J.; Huber, H. H.; Torrent, M.; Prueksaritanont, T.; Li, C.; Slaughter, D. E.; Mahan, E.; Fernandez-Metzler, C.; Yan, Y.; Kuo, L. C.; Kohl, N. E.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part 9: The discovery of KSP inhibitor MK-0731 for the treatment of taxane-refractory cancer. J. Med. Chem. 2008, 51, 4239-4252.
32. It is well known, both internally at Merck and in the literature, that increasing polarity and/or hydrogen bond donors/acceptors of drug molecules is a reliable strategy to minimize interaction with the hERG channel. See: Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. J. Med. Chem. 2006, 49, 5029-5046.
33. Cerny, M. A.; Hanzlik, R. P. Cyclopropylamine inactivation of cytochromes P450: Role of metabolic intermediate complexes. Arch. Biochem. Biophys. 2005, 426, 265-275.
34. Sorbera, L. A.; Bolos, J.; Serradell, N.; Bayés, M. Ispinesib mesilate. Drugs Future 2006, 31, 778-787.
35. Goncharov, N. V.; Jenkins, R. O.; Radilov, A. S. Toxicology of fluoroacetate: A review, with possible directions for therapy research. J. Appl. Toxicol. 2006, 26, 148-161.
36. van Niel, M. B.; Collins, I.; Beer, M. S.; Broughton, H. B.; Cheng, S. K. F.; Goodacre, S. C.; Heald, A.; Locker, K. L.; MacLeod, A. M.; Morrison, D.; Moyes, C. R.; O'Connor, D. O.; Pike, A.; Rowley, M.; Russell, M. G. N.; Sohal, B.; Stanton, J. A.; Thomas, S.; Verrier, H.; Watt, A. P.; Castro, J. L. Fluorination of 3-(3- (piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl) indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles. J. Med. Chem. 1999, 42, 2087-2104.
37. Tao, W.; South, V. J.; Zhang, Y.; Davide, J P.; Farrell, L.; Kohl, N. E.; Sepp-Lorenzino, L.; Lobell, R. B. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005, 8, 49-59.
38. Giannakakou, P.; Sackett, D. L.; Kang, Y.-K.; Zhan, Z.; Buters, J. T. M.; Fojo, T.; Poruchynsky, M. S. Paclitaxel-resistant human ovarian cancer cells have mutant oo-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 1997, 272, 17118-17125.
39. Coleman, P. J.; Schreier, J. D.; Cox, C. D.; Fraley, M. E.; Garbaccio, R. M.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Lobell, R. B.; Rickert, K.; Tao, W.; Diehl, R. E.; South, V. J.; Davide, J. P.; Kohl, N. E.; Yan, Y.; Kuo, L.; Prueksaritanont, T.; Li, C.; Mahan, E. A.; Fernandez-Metzler, C.; Salata, J. J.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5- diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem. Lett. 2007, 17, 5390-5395.
40. Garbaccio, R. M.; Tasber, E. S., Neilson, L. A., Coleman, P. J., Fraley, M.A., Olson, C., Bergman, J., Torrent, M., Buser, C. A., Rickert, K., Walsh, E. S., Hamilton, K., Lobell, R. B., Tao, W., South, V. J., Diehl, R. E., Davide, J. P., Yan, Y., Kuo, L. C., Li, C., Prueksaritanont, T., Fernandez-Metzler, C., Mahan, E. A., Slaughter, D. E., Salata, J. J., Kohl, N. E., Huber, H. E. and Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem. Lett. 2007, 17, 5671-5676.
41. Stein, M. N.; Rubin, E. H.; Taber, K.; Fernandez, R. C.; Agrawal, N. G. B.; Vandrendreis, E.; Hsu, K.; Walker, A.; Holen, K.; Xue, L.; Cooley, P. C. Wilding, G. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in patients with solid tumors. J. Clin. Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 2548.
42. Cytokinetics Website. Ispinisb. http://www.cytokinetics.com/ispinesib (Accessed December 20, 2010).
43. Cytokinetics Website. SB-743921. http://www.cytokinetics.com/sb_743921 (Accessed December 20, 2010).
44. Shah, J. J.; Cohen, A. D.; Zonder, J. A.; Kaufman, J. L.; Burt, S. M.; Freeman, B. B.; Rush, S.; Ptaszynski, A. M.; Orlowski R. Z.; Lonial S. Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM). J. Clin. Oncol. (Meeting Abstracts) 2010, vol. 28, no. 15_suppl 8132.
45. Array Biopharma Website. Product Pipeline. http://www.arraybiopharma. com/ProductPipeline/Cancer/KSP.asp (Accessed December 20, 2010).